Change over period: —
NSE · TORNTPHARM
TORRENT PHAR
-10.0% from the 52-week high · +25.1% above the low
Torrent Pharmaceuticals Ltd. engages in the research, development, manufacture, and marketing of generic pharmaceutical formulations. The company is headquartered in Ahmedabad, Gujarat and currently employs 13,573 full-time employees. The firm is focused on various therapeutic segments, such as cardiovascular (CV), central nervous system (CNS), gastrointestinal (GI), vitamins minerals nutrients (VMN), anti-diabetes (AD), pain, gynecology, and dermatology. The firm is engaged in research, development, manufacturing, marketing and distribution of branded and generic pharmaceutical formulations in India and internationally. Its pediatric product brands include Tedibar, Atogla, Spoo and B4 Nappi. Its acne/facecare products brands include Clinmiskin, ACNEMOIST, TRACNILO and fash. The firm's hair/scalp care products brands include Proanagen, Perlice, Permite and NOSKURF. Its manufacturing facilities are located in the states of Gujarat, Himachal Pradesh, Madhya Pradesh, Andhra Pradesh and Sikkim. The firm's primary channel of distribution is through the wholesale drug distributors, stockiest and retail pharmacies.
The short version. TORRENT PHAR reported revenue of ₹4,979 crore for Sep 2026, up 50.8% from a year earlier. Net profit was ₹534 crore (down 9.6% year on year). Return on equity was 25.8% in Mar 2026. Promoter holding was 60.78% in Sep 2026, down 7.53 points over 8 quarters.
1 · The price
How has the stock traded?
TORRENT PHAR trades 10.0% below its 52-week high and 25.1% above its 52-week low.
2 · The business
Is it growing?
Sep 2026 revenue of ₹4,979 cr.
Sep 2026 net profit of ₹534 cr.
7.2 pts lower than a year earlier.
Revenue compounded at 12.8% over the same 3 years.
Reported results · ₹ crore
Revenue and profit
Show the numbers
Quarterly
| Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 4979 | 4921 | 4197 | 3303 | 3302 | 3178 | 2959 | 2809 |
| Net profit | 534 | 566 | 389 | 635 | 591 | 548 | 498 | 503 |
| Net margin % | 10.7 | 11.5 | 9.3 | 19.2 | 17.9 | 17.2 | 16.8 | 17.9 |
| EPS (₹) | 14.04 | 16.72 | 11.49 | 18.76 | 17.46 | 16.19 | 14.71 | 14.86 |
Annual
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | 13980 | 11516 | 10728 | 9620 | 8508 | 8005 | 7939 | 7673 |
| Net profit | 2163 | 1911 | 1656 | 1245 | 777 | 1252 | 1025 | 436 |
| Net margin % | 15.5 | 16.6 | 15.4 | 12.9 | 9.1 | 15.6 | 12.9 | 5.7 |
| EPS (₹) | 63.91 | 56.46 | 48.93 | 36.79 | 22.96 | 36.99 | 30.29 | 12.88 |
3 · The quality
How well does it turn capital into profit?
Return on equity was 25.8% in Mar 2026; debt to equity is 1.76.
Profitability · 4 years
Returns and margins
| Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | |
|---|---|---|---|---|
| Return on equity % | 25.8 | 25.2 | 24.1 | 20.1 |
| Return on capital % | 9.1 | 28.5 | 28.1 | 22.8 |
| EBITDA margin % | 31.5 | 32.2 | 32.6 | 29.9 |
| Net margin % | 15.6 | 16.6 | 15.3 | 12.9 |
Compound growth
Revenue vs profit
| 3 years | 5 years | |
|---|---|---|
| Revenue CAGR | 12.8% | 11.5% |
| Profit CAGR | 20.2% | 11.6% |
4 · The owners
Who holds it, and are they adding?
Down 7.53 pts over 8 quarters.
Up 1.05 pts over 8 quarters.
Up 5.11 pts over 8 quarters.
+90 versus the previous month.
Shareholding pattern (%)
Quarter by quarter
| Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Sep 2026 | Change | |
|---|---|---|---|---|---|---|---|---|---|
| Promoter | 68.31 | 68.31 | 68.31 | 68.31 | 68.31 | 68.31 | 68.31 | 60.78 | -7.53 |
| FII | 16.17 | 16.31 | 16.09 | 15.92 | 16.13 | 16.18 | 15.44 | 17.22 | +1.05 |
| DII | 8.35 | 8.35 | 8.65 | 9.28 | 9.14 | 9.06 | 9.83 | 13.46 | +5.11 |
| Public | 7.17 | 7.03 | 6.94 | 6.49 | 6.42 | 6.45 | 6.42 | 8.54 | +1.37 |
Mutual fund holdings · Oct 2026
390 schemes hold this stock
300 the month before.
- ADITYA BIRLA SUN LIFE PHARMA & HEALTHCARE FUND8.83% of NAV
- quant Healthcare Fund8.46% of NAV
- PGIM INDIA HEALTHCARE FUND8.34% of NAV
- Baroda BNP Paribas Health and Wellness Fund7.74% of NAV
- ICICI Prudential Nifty Pharma ETF6.71% of NAV
- Nippon India Nifty Pharma ETF6.71% of NAV
- ICICI Prudential Nifty Pharma Index Fund6.71% of NAV
- Mirae Asset Healthcare Fund6.41% of NAV
5 · The model view
What does our factor model say?
Factor scores, model flags and screen results for TORRENT PHAR are part of the Wright portfolio review.
Run your free portfolio reviewWatchouts
What to review
Model flags are shown inside the portfolio review, alongside your other holdings.
Related stocks
Other Pharmaceuticals & Biotechnology stocks
Quick answers
Common questions about TORRENT PHAR
What is the TORRENT PHAR share price?
TORRENT PHAR (TORNTPHARM) last closed at ₹4,611.00, up 0.01% on the day. Its 52-week range is ₹3,686.50 to ₹5,122.80.
What is the market cap of TORRENT PHAR?
TORRENT PHAR has a market capitalisation of about ₹176,413 crore. Its price-to-earnings ratio is 78.1.
How are TORRENT PHAR's latest results?
TORRENT PHAR reported revenue of ₹4,979 crore for Sep 2026, up 50.8% from a year earlier. Net profit was ₹534 crore (down 9.6% year on year). Return on equity was 25.8% in Mar 2026. Promoter holding was 60.78% in Sep 2026, down 7.53 points over 8 quarters.
Who owns TORRENT PHAR?
As of Sep 2026, shareholding was: Promoter 60.78%, FII 17.22%, DII 13.46%, Public 8.54%.
How many mutual funds hold TORRENT PHAR?
390 mutual fund schemes held TORRENT PHAR in October 2026. That compares with 300 the month before.
Corporate actions
Recent dividends, bonuses and splits
- 29 May 2026 · Final Dividend - Rs. 9
- 18 Feb 2026 · Interim Dividend - Rs. 29
- 20 Jun 2025 · Final Dividend - Rs. 6
- 31 Jan 2025 · Interim Dividend - Rs. 26
- 21 Jun 2024 · Final Dividend - Rs. 6
- 12 Feb 2024 · Interim Dividend - Rs. 22
Financials are as reported by the company (consolidated), in ₹ crore. Source: FinEdge exchange filings feed. Figures can differ from other sites because of one-off items and restatements. Callouts above are arithmetic on reported data, not recommendations.
Research data on this page is provided under Wright Research's SEBI Research Analyst registration. The Terms & Conditions of our Research Analyst services apply.